214 related articles for article (PubMed ID: 37374314)
1. Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients.
Gesualdo C; Rossi S; Iodice CM; Guarino F; Petrella M; D'Agostino FA; Perrotta R; Simonelli F
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374314
[No Abstract] [Full Text] [Related]
2. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
3. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
[TBL] [Abstract][Full Text] [Related]
4. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
6. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
7. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.
Bilgic A; Kodjikian L; de Ribot FM; Spitzer MS; Vasavada V; Gonzalez-Cortes JH; Sudhalkar A; Chakraborty S; Mathis T
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1161-1167. PubMed ID: 38063874
[TBL] [Abstract][Full Text] [Related]
9. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
10. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
11. Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.
Weng CC; Chi SC; Lin TC; Huang YM; Chou YB; Hwang DK; Chen SJ
PLoS One; 2024; 19(4):e0301096. PubMed ID: 38564612
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
13. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months.
Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046
[TBL] [Abstract][Full Text] [Related]
14. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
15. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study.
Tamashiro T; Tanaka K; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Ogasawara M; Sugano Y; Yamamoto A; Kataoka K; Izumi T; Kawai M; Mori R; Sekiryu T; Okada AA; Iida T; Koizumi H;
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1857-1865. PubMed ID: 35034215
[TBL] [Abstract][Full Text] [Related]
16. Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting.
Pastore MR; Milan S; Cirigliano G; Tognetto D
Sci Rep; 2024 Jan; 14(1):1441. PubMed ID: 38228633
[TBL] [Abstract][Full Text] [Related]
17. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
18. One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.
Almuhtaseb H; Kanavati S; Rufai SR; Lotery AJ
Eye (Lond); 2017 Jun; 31(6):878-883. PubMed ID: 28186507
[TBL] [Abstract][Full Text] [Related]
19. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
20. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
